Lilly stock caught up in wave of uncertainty
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
Eli Lilly and Co.
Articles
Lilly’s U.S. weight-loss drug shortage ends, curtailing copycats
The FDA had previously said Lilly’s drugs were out of shortage and that making copies must cease in October. Compounders sued, causing the FDA to pause enforcement while it reevaluated its decision.
State approves $60M for LEAP District development for Lilly, Meta projects
The state will eventually recoup much of that investment when LEAP land is sold to tenants, officials from the Indiana Economic Development Corp. said.
IEDC requests additional $60M for Lilly, Meta land, infrastructure at LEAP
The state’s job-creation agency is seeking $27 million to purchase about 307 acres and pay for deposits and option payments for additional land west of Interstate 65. Another $33 million is being sought for infrastructure work.
Lilly CEO predicts obesity-treatment Zepbound will become drugmaker’s top drug by 2025
David Ricks told a lunch audience at the Economic Club of Washington, D.C., that Zepbound could quickly become the most popular drug in the 148-year-old company’s history.
Lilly to test obesity drugs for addiction treatment, CEO says
Lilly also approved a program to buy back as much as $15 billion of its own shares amid rapid growth fueled by Zepbound and Mounjaro.
Roche data shows simple blood test can help determine if someone has Alzheimer’s
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and Drug Administration granted a breakthrough device designation to the product.
Lilly to spend $3B to expand Wisconsin factory
Under pressure to keep up with soaring demand for drug treatments for obesity, diabetes and other diseases, Eli Lilly and Co. is planning its single largest U.S. manufacturing investment outside of Indiana.
Trial shows Lilly’s Zepbound helps patients lose far more weight than competing drug
Eli Lilly and Co. said its weight-loss treatment Zepbound helped patients lose 47% more relative weight than competitor Novo Nordisk’s obesity treatment Wegovy in a head-to-head clinical trial.
Lilly shares get bump from pricey Biden proposal for covering weight-loss drugs
While the proposed rule would give millions of people access to weekly injectables like Eli Lilly and Co.’s Zepbound that have helped people shed pounds, it would cost taxpayers as much as $35 billion over the next decade.
UIndy lands $5M gift from graduate and retired Lilly exec Stephen Fry
The money will go to start three programs designed to give students real-world business experience along with their classroom experience.
Lilly expands research in Singapore with focus on sleep quality
Eli Lilly and Co. plans to set up a $31 million digital health innovation hub in Singapore, expanding its research and development in the city-state.
Lilly CEO Dave Ricks named Watanabe Award winner
Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care innovation.
UPDATE: Lilly shares tumble on earnings report that falls short of Wall Street expectations
The Indianapolis-based drugmaker missed expectations on sales of two popular drugs, diabetes treatment Mounjaro and weight-loss treatment Zepbound, which it attributed to inventory decreases in the wholesaler channel.
UK regulator approves Lilly’s new Alzheimer’s drug but government won’t pay for it
Britian’s National Institute for Health and Care Excellence said more evidence was needed to prove Kisunla’s worth. Lilly says a year’s worth of treatment is $32,000.
Amid backlash, FDA changes course over shortage of Lilly weight-loss drugs
The U.S. Food and Drug Administration said it would not take enforcement action—for now—against pharmacies making their own versions of weight-loss drugs based on Eli Lilly’s tirzepatide.
Alzheimer’s patients and their families hear a new word: Progress
Two new drugs—including one from Indianapolis-based Eli Lilly—and better detection methods offer promise for people dealing with the disease.
IBJ Podcast: What’s the potential impact of Lilly’s $4.5B ‘medicine foundry’ in Lebanon?
Lilly wants to know how to improve new medicines and speed them to market more quickly. The project promises hundreds of high-paying jobs and could help lift Lilly among a handful of the most valuable companies in America.
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
Lilly weight-loss drug copycat makers sue FDA for taking drugs off shortage list
The plaintiffs allege that the shortage of Lilly’s drugs isn’t actually over, and that the agency’s decision deprives patients of important medicines by restricting compounding.